BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25518340)

  • 1. [Current status of castration resistant prostate cancer basic research].
    Sakamoto S; Ichikawa T
    Nihon Rinsho; 2014 Dec; 72(12):2097-102. PubMed ID: 25518340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The concept and mechanisms of castration-resistant prostate cancer].
    Naito S; Shiota M
    Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of castration-resistant prostate cancer translational research].
    Maeno A; Habuchi T
    Nihon Rinsho; 2016 Jan; 74(1):40-4. PubMed ID: 26793877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.
    Sobhani N; Generali D; D'Angelo A; Aieta M; Roviello G
    Invest New Drugs; 2018 Dec; 36(6):1133-1137. PubMed ID: 30083960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
    Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
    PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
    Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
    Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular biology of castration-resistant prostate cancer].
    Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.
    Brand LJ; Dehm SM
    Curr Drug Targets; 2013 Apr; 14(4):441-9. PubMed ID: 23410127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The link between androgen receptor splice variants and castration-resistant prostate cancer.
    Sprenger CC; Plymate SR
    Horm Cancer; 2014 Aug; 5(4):207-17. PubMed ID: 24798453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the adaptive molecular landscape of castration-resistant prostate cancer.
    Wyatt AW; Gleave ME
    EMBO Mol Med; 2015 Jul; 7(7):878-94. PubMed ID: 25896606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.
    Udager AM; Shi Y; Tomlins SA; Alva A; Siddiqui J; Cao X; Pienta KJ; Jiang H; Chinnaiyan AM; Mehra R
    Prostate; 2014 Sep; 74(12):1199-208. PubMed ID: 25043157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.